ViaCyte Updates on Stem Cell-Derived Cell Replacement Therapies for Type 1 Diabetes

ViaCyte, Inc., a regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments, announced 165 new patents were issued last year relating to their implantable cell replacement therapies for insulin-requiring diabetes and other potential indications.

“ViaCyte’s intellectual property covers methods to manufacture and composition of matter for various cell types made from pluripotent stem cell sources, including embryonic and induced pluripotent stem cells, for cell replacement therapies,” said Dr. Paul Laikind, president and CEO of ViaCyte in a company press release.

“The newly issued patents reflect ViaCyte’s exceptional work in the field and further support our leadership as we work to deliver transformative cell therapies for insulin-requiring diabetes. These and our previously issued patents also position us to expand our programs into other important therapeutic areas at the appropriate time and make us a good strategic partner for other companies that wish to work in the cell therapy field,” he added.

Many of the new patents are directed to compositions and methods for culturing human pluripotent stem cells and differentiating them to pancreatic progenitor and later stage cells including endocrine cells.

Other patents are directed to the Company’s combination product as well as delivery device designs.

The new patents have been issued in the United States, Canada, Japan, Korea, Hong Kong, Singapore, India, China, Australia, Russia, Poland, Ireland, the United Kingdom, Belgium, Denmark, Germany, France, Italy, Switzerland, and Spain.

Laikind will be discussing this and other news when he gives a company presentation at Biotech ShowcaseTM on Monday, January 7 at 11:30 am in Franciscan C at the Hilton San Francisco Union Square.